Research, Innovation and Education in Pharma, Medicine and Environment Applications

The Institute for Medical Engineering and Medical Informatics works with hospitals and industry to carry out R&I in diagnostic and therapeutic systems. It develops patient-oriented devices, implants and methods, as well as advanced tools for medical data processing and analysis. Click here for the Institute's website.

The Institute of Pharmaceutical Technology maps industrial processes from raw ingredients to the final form of the drug. Its activities cover drug formulation, manufacture and delivery, with specific focus on dosage form design, production processes, quality, pharmacokinetics and personalisation. It has close partnerships with leading European and international pharma firms and start-ups. Click here for the Institute's website.

The Institute for Chemistry and Bioanalytics collaborates with agro, food, pharma and bio-chemical industries on cutting edge research in fields such as sustainable processes, feedstock identification and preparation, advanced (nano)materials and organ function diagnostic systems. It has expertise in various areas, such as the analysis of large data sets (data science), and the ability to develop and implement processes up to pilot scale, including safety assessments. Click here for the Institute's website.

The Institute for Ecopreneurship conducts lab and pilot scale interdisciplinary R&I in the circular (bio)economy and environmental restoration. It creates innovative solutions for waste stream conversion into marketable products and for treatment, detoxification and regeneration of contaminated water and soil. Sustainability is assessed with comprehensive ecotoxicological studies and life cycle analyses. It has close partnerships with leading EU biobased and bioremediation industries and start-ups. Click here for the Institute's website.

• EU JPND project: “Multinational research projects on Personalised Medicine for Neuro-degenerative Diseases” (ORGTHERAPY) (EUR 98’490.–)
• Eurostars project 113627: “Suppressing Tremor to A Bearable Level” (STABLE) (EUR 198’300.–)
• Eurostars project 113479: “3D cell culture platform for personalized ovarian cancer therapy selection” (EUR 223’240.–)

• SPIRITS: Smart 3D-printed interactive robot for interventional radiology and surgery (EUR 299’258.–)
• PERSONALIS: Platform for personalized medicine for autoimmune diseases (EUR 335’362.–)
• TRIMABONE: 3d printing for resorbable implants (EUR 200’000.–)

• Wellcome Trust (UK), a renowned global charitable foundation: “Discovery of anti-DENV Antibodies Using Artificial Intelligence” (EUR 897’535.–)
• Adalbert-Raps Stiftung: “Effizienzsteigerung von Algenkultivierungsprozessen” (EUR 131’050.−)
• UNIDO: Provision of Eco-lndustrial Park related services in Peru (EUR 85’000.–)

• Structural and Functional Characterisation of the Primer Synthesis of Archaeoeukaryotic Primases (SNSF) (EUR 457’721.–)
• The underestimated role of the human omentum in metastatic spread (SNSF) (EUR 532’760.–)
• Efficient colonic drug delivery (Bridge – Discovery) (EUR 684’000.–)
• Implemention of Adverse Outcome Pathway in a «plug&play» Microfluidics System. Liver Fibrosis as a Proof of Principle (Bridge – Discovery) (EUR 705’696.–)

• Botnar Research Centre for Child Health (BRCCH): “DAVINCI: Development and Validation of a Lateral Flow Test to Detect COVID-19 Antigens and Immunity in Saliva (EUR 473’000.–)

• BAFU Project: Review study on the use of biotests for the assessment of industrial wastewater and proposal of an evaluation concept (EUR 175’200.–)

• Development of a dual mode marker system for X-ray and optical stereoscopic camera tracking (17077.2 PFLS-LS) (EUR 405’033.–)
• Development of a Nanoporous Antibacterial Surface for Titanium Implants by reverse-pulse electrochemical Copper deposition (NANTI) (14293.2;9 PFNM-NM) (EUR 111’933.–)
• Targeted vitamin delivery to the microbiome for improved gut health; in collaboration with DSM Nutritional Products (46093.1 IP-LS) (EUR 626’490.–)
• Automated LADME Assay platform Based on Advanced Microphysiological Arrays (ALABAMA) (44386.1 IP-LS) (EUR 790’994.–)
• Lyopan technology for orally dispersible tablets (18800.2 PFIW-IW) (EUR 433’222.–)
• Drugs for wound healing (25840.1 PFLS-LS) (EUR 698’050.–)
• Topical antiinfectives against leishmaniasis (34227.1 IP-LS) (EUR 397’351.–)